Simulations Plus shareholders will receive $18.50 per share in cash. This deal values the company at $375 million, according to Fierce Biotech. The acquisition by Altaris Capital offers a 26% premium to Simulations Plus's recent average price as of June 15, 2026. The all-cash transaction provides immediate liquidity for investors.
Simulations Plus built a reputation for independent innovation in drug discovery software. However, its acquisition by Altaris Capital marks a strategic shift towards private equity-driven growth, potentially altering the company's long-standing research and development priorities.
The life sciences software sector will likely see further consolidation as private equity firms capitalize on specialized tools driving pharmaceutical R&D efficiency. Aggressive financial backing now appears essential for scaling, even for established innovative companies.
The Deal at a Glance
- Simulations Plus, Inc. announced a definitive agreement for acquisition by Altaris, LLC in an all-cash deal valuing the company at approximately $375 million, according to TipRanks.
- Altaris, through its affiliates SP Evolution HoldCo II, LLC and SP Evolution BidCo II, LLC, will acquire Simulations Plus, Inc. in a merger, reports Stock Titan.
- The acquisition price is $18.50 per share, as reported by Investing.
- Benzinga also reports the acquisition of Simulations Plus by Altaris is valued at approximately $375 million.
The formal agreement and specific acquiring entities confirm a structured private equity takeover. This meticulous structuring suggests Altaris's intent to rapidly operationalize its investment and leverage Simulations Plus's assets within a broader portfolio strategy.
